|
1.
|
|
11 p, 1.4 MB |
Prognostic gene expression signature for high-grade serous ovarian cancer
/
Millstein, Joshua (University of Southern California) ;
Budden, Timothy (The University of Manchester) ;
Goode, Ellen L. (Mayo Clinic) ;
Anglesio, Michael (University of British Columbia) ;
Talhouk, Aline (University of British Columbia) ;
Intermaggio, Maria Paola (University of NSW Sydney) ;
Leong, Hueisan (Peter MacCallum Cancer Center) ;
Chen, Stephanie S. (Cedars-Sinai Medical Center) ;
Elatre, Wafaa A. (University of Southern California) ;
Gilks, Cyril Blake (University of British Columbia) ;
Nazeran, Tayyebeh M. (University of British Columbia) ;
Volchek, Mila (Royal Women's Hospital) ;
Bentley, Rex C. (Duke University Hospital) ;
Wang, Chen (Mayo Clinic) ;
Chiu, Derek S. (University of British Columbia) ;
Kommoss, Stefan (Tuebingen University Hospital) ;
Leung, Samuel C. Y. (University of British Columbia) ;
Senz, Janine (University of British Columbia) ;
Lum, Amy (University of British Columbia) ;
Chow, Veronica (University of British Columbia) ;
Sudderuddin, Hanwei (University of British Columbia) ;
Mackenzie, Robertson (University of British Columbia) ;
George, Joshy (The Jackson Laboratory for Genomic Medicine) ;
Fereday, Sian (University of Melbourne) ;
Hendley, Joy (University of Melbourne) ;
Traficante, Nadia (University of Melbourne) ;
Steed, Helen (Royal Alexandra Hospital) ;
Koziak, Jennifer M. (Alberta Health Services-Cancer Care) ;
Köbel, Martin (Foothills Medical Center) ;
McNeish, Iain (University of Glasgow) ;
Goranova, Teodora Evgenieva (University of Cambridge) ;
Ennis, Darren P. (University of Glasgow) ;
Macintyre, Geoff (University of Cambridge) ;
Silva De Silva, D. (University of Cambridge) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
García Donas, J. (HM Hospitales D Centro Integral Oncológico HM Clara Campal) ;
Hernando, Susana (Hospital Universitario Funcacion Alcorcon) ;
Rodriguez, Gustavo C. (University of Chicago) ;
Cushing-Haugen, Kara L. (Fred Hutchinson Cancer Research Center) ;
Harris, Holly Ruth (University of Washington) ;
Greene, Casey S. (University of Pennsylvania) ;
Zelaya, René A. (Geisel School of Medicine at Dartmouth) ;
Behrens, Sabine (German Cancer Research Center (DKFZ)) ;
Fortner, Renée T. (German Cancer Research Center (DKFZ)) ;
Sinn, Hans-Peter (Heidelberg University Hospital (Alemanya)) ;
Herpel, Esther (University Hospital and German Cancer Research Center) ;
Lester, Jenny (Cedars-Sinai Medical Center) ;
Lubinski, Jan (Pomeranian Medical University) ;
Oszurek, Oleg (Pomeranian Medical University) ;
Tołoczko, Aleksandra D. (Pomeranian Medical University) ;
Cybulski, Cezary (Pomeranian Medical University) ;
Menkiszak, Janusz Leszek (Pomeranian Medical University) ;
Pearce, Celeste Leigh (University of Southern California Norris Comprehensive Cancer Center) ;
Pike, Malcolm C. (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Tseng, Chiuchen Cheng (University of Southern California) ;
Alsop, Jennifer (University of Cambridge) ;
Rhenius, Valerie (University of Cambridge) ;
Song, Hongan (University of Cambridge) ;
Jimenez-Liñan, Mercedes (Addenbrooke's Hospital NHS Trust) ;
Piskorz, Anna M. (University of Cambridge) ;
Gentry-Maharaj, Aleksandra (University College London) ;
Karpinskyj, Chloe (University College London) ;
Widschwendter, M. (University College London) ;
Singh, Naveena K. (Barts Health National Health Service Trust) ;
Kennedy, Catherine J. (Westmead Hospital) ;
Harnett, Paul R. (University of Sidney) ;
Gao, Bo (Westmead Hospital) ;
Johnatty, Sharon E. (QIMR Berghofer Medical Research Institute (Brisbane, Austràlia)) ;
Sayer, Robyn A. (Westmead Hospital) ;
Boros, Jessica (Westmead Hospital) ;
Winham, Stacey J. (Mayo Clinic) ;
Keeney, Gary L. (Mayo Clinic) ;
Kaufmann, Scott H. (Mayo Clinic) ;
Larson, Melissa C. (Mayo Clinic) ;
Luk, Hugh W. (University of Hawaii Cancer Center) ;
Hernandez, Brenda Y. (University of Hawaii Cancer Center) ;
Thompson, Pamela J. (Cedars-Sinai Medical Center) ;
Wilkens, Lynne Ross (University of Hawaii Cancer Center) ;
Carney, Michael E. (University of Hawaii) ;
Trabert, Britton (National Cancer Institute) ;
Lissowska, Jolanta (M Sklodowska Curie National Research Institute of Oncology) ;
Brinton, Louise Annette (National Cancer Institute) ;
Sherman, Mark E. (Mayo Clinic College of Medicine) ;
Bodelón, Clara (National Cancer Institute) ;
Hinsley, Samantha (University of Glasgow) ;
Lewsley, Liz Anne (University of Glasgow) ;
Glasspool, Rosalind M. (University of Glasgow) ;
Banerjee, Susana (The Royal Marsden NHS Foundation Trust and Institute of Cancer Research) ;
Stronach, Euan A. (Imperial College London) ;
Haluska, Paul J. (Mayo Clinic) ;
Ray-Coquard, Isabelle Laure (Centre Leon Berard and University Claude Bernard Lyon 1) ;
Mahner, Sven (LMU Munich) ;
Winterhoff, Boris J. N. (University of Minnesota) ;
Slamon, Dennis J. (University of California at Los Angeles) ;
Levine, Douglas A. (NYU Langone Medical Center) ;
Kelemen, Linda E. (Medical University of South Carolina) ;
Benitez, Javier J. (Centro Nacional de Investigaciones Oncológicas) ;
Chang-Claude, J. (University Medical Center Hamburg-Eppendorf) ;
Gronwald, Jacek (Pomeranian Medical University) ;
Wu, Anna H. (University of Southern California) ;
Menon, Usha (MRC University College London) ;
Goodman, Marc T. (Cedars-Sinai Medical Center) ;
Schildkraut, Joellen M. (Emory University) ;
Wentzensen, Nicolas A. (National Cancer Institute) ;
Brown, Robert (Imperial College London) ;
Berchuck, Andrew (Duke University Hospital) ;
Gayther, Simon A. (Cedars-Sinai Medical Center) ;
García, M. J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Henderson, Michelle J. (University of NSW Sydney) ;
Rossing, Mary Anne (University of Washington) ;
Beeghly-Fadiel, Alicia (Vanderbilt University School of Medicine) ;
Fasching, Peter Andreas (Friedrich-Alexander-University Erlangen-Nuremberg) ;
Orsulic, Sandra (Cedars-Sinai Medical Center) ;
Karlan, Beth Y. (Cedars-Sinai Medical Center) ;
Konecny, Gottfried Ewald (University of California at Los Angeles) ;
Huntsman, David G. (BC Cancer Research Centre) ;
Brenton, James D. (University of Cambridge) ;
Doherty, Jennifer Anne (University of Utah) ;
Pharoah, Paul D. P. (University of Cambridge) ;
Ramus, Susan (University of NSW Sydney) ;
Universitat Autònoma de Barcelona
Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. [...]
2020 -  10.1016/j.annonc.2020.05.019
Annals of oncology, Vol. 31 Núm. 9 (01 2020) , p. 1240-1250
|
|
|
2.
|
|
8 p, 823.8 KB |
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)
/
González-Santiago, S. (Hospital Universitario San Pedro de Alcántara) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Aguirre, Elena (Hospital Quirónsalud) ;
Alés-Martínez, J.E. (Hospital Nuestra Señora de Sonsoles (Àvila)) ;
Andrés, R. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Balmaña Gelpí, Judith (Hospital Universitari Vall d'Hebron) ;
Graña, B. (Complexo Hospitalario Universitario (CHUAC)) ;
Herrero, A. (Hospital Universitario Miguel Servet (Saragossa)) ;
Llort, Gemma (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
the SEOM Hereditary Cancer Working Group ;
Universitat Autònoma de Barcelona
Mutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes included in multigene panels have increased the genetic diagnosis of hereditary breast and ovarian cancer families by 50%. [...]
2020 - 10.1007/s12094-019-02262-0
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 193-200
|
|
|
3.
|
|
18 p, 3.7 MB |
Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer : A Multicentric Propensity Score Study
/
Llueca, Antoni (Department of Medicine, University Jaume I) ;
Ibañez, Maria Victoria (Department of Mathematics, University Jaume I) ;
Cascales, Pedro (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Gil-Moreno, Antonio 1965- (Vall d'Hebron Institut d'Oncologia) ;
Bebia, Vicente (Vall d'Hebron Institut d'Oncologia) ;
Ponce, Jordi (Department of Gynecology, University Hospital of Bellvitge) ;
Fernández-González, Sergi (Department of Gynecology, University Hospital of Bellvitge, 08907 Barcelona, Spain; (J.P.); (S.F.)) ;
Arjona-Sanchez, Alvaro (University Hospital Reina Sofia) ;
Muruzabal, Juan Carlos (Department of Gynecologic Oncology, Complejo Hospitalario de Navarra) ;
Veiga, Nadia (Department of Gynecologic Oncology, Complejo Hospitalario de Navarra) ;
Díaz-Feijoo, Berta (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Celada, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gilabert-Estelles, Juan (Department of Obstetrics and Gynecology, University General Hospital of Valencia) ;
Aghababyan, Cristina (Department of Obstetrics and Gynecology, University General Hospital of Valencia) ;
Lacueva, Javier (Department of General Surgery, University General Hospital of Elche) ;
Calero, Alicia (Department of General Surgery, University General Hospital of Elche) ;
Segura-Sampedro, Juan José (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Maiocchi, Karina (Department of General Surgery, University General Hospital of Castellon) ;
Llorca, Sara (Department of General Surgery, University General Hospital of Castellon) ;
Villarin, Alvaro (Department of General Surgery, University General Hospital of Castellon) ;
Climent, Maria Teresa (Department of Medicine, University Jaume I) ;
Delgado, Katty (Department of Medicine, University Jaume I) ;
Serra Rubert, Anna (Department of Medicine, University Jaume I) ;
Gomez-Quiles, Luis (Department of General Surgery, University General Hospital of Castellon) ;
Llueca, Maria (Hospital Universitari Joan XXIII de Tarragona) ;
Universitat Autònoma de Barcelona
Advanced ovarian cancer (Stages III-IV) continues to be one of the gynecological tumors with the highest mortality. Standard treatment consists of debulking surgery and subsequent adjuvant chemotherapy. [...]
2023 - 10.3390/cancers15174271
Cancers, Vol. 15 (august 2023)
|
|
|
4.
|
|
17 p, 911.8 KB |
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting
/
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gil-Martín, Marta (Hospital Universitari de Bellvitge) ;
Gaba, Lydia (Hospital Clínic i Provincial de Barcelona) ;
Teruel, Iris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Taus, Álvaro (Hospital del Mar (Barcelona, Catalunya)) ;
Fina, Claudia (Institut Català d'Oncologia) ;
Masvidal, Maria (Hospital Universitari de Reus) ;
Murata, Paola (Hospital Universitari Arnau de Vilanova) ;
Fernández-Plana, Julen (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Martínez Bueno, Alejandro (Hospital Quirón Dexeux) ;
Pérez, Cristina (Xarxa Sanitària i Social Santa Tecla) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez, Valerie (Hospital de Tortosa Verge de la Cinta) ;
Cros Costa, Sara (Hospital General de Granollers) ;
Parera, Marta (Hospital Universitari de Vic) ;
Zanui, Montserrat (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Catot, Silvia (Xarxa Assistencial Universitària de Manresa) ;
Pardo, Beatriz (Hospital Universitari de Bellvitge) ;
Plaja, Andrea (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Barretina-Ginesta, Maria-Pilar (Institut Català d'Oncologia)
Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. [...]
2022 - 10.3390/cancers14184414
Cancers, Vol. 14 (september 2022)
|
|
|
5.
|
|
13 p, 1.7 MB |
A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management
/
Bradbury, Melissa (Hospital Universitari Vall d'Hebron) ;
Borràs, Eva (Universitat Pompeu Fabra) ;
Vilar, Marta (Hospital Universitari Vall d'Hebron) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Sanchez Iglesias, Jose Luis (Hospital Universitari Vall d'Hebron) ;
Pérez-Benavente, Assumpció (Hospital Universitari Vall d'Hebron) ;
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ;
Fàbrega-Santamaria, Anna (Hospital Universitari Vall d'Hebron) ;
Sabidó, Eduard (Universitat Pompeu Fabra) ;
Universitat Autònoma de Barcelona
High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. [...]
2022 - 10.1186/s12967-022-03816-7
Journal of translational medicine, Vol. 20 (december 2022)
|
|
|
6.
|
|
10 p, 3.7 MB |
SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis
/
Gutiérrez-Chamorro, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Bernat-Peguera, Adrià (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ezeonwumelu, I.J (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teruel, Iris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Clotet Sala, Bonaventura (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas) ;
Riveira-Muñoz, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Romeo, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ballana, Ester (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase which has been proposed as a putative prognostic factor in haematological cancers and certain solid tumours, although with controversial data. [...]
2023 - 10.3389/fimmu.2023.1112761
Frontiers in immunology, Vol. 14 (february 2023)
|
|
|
7.
|
|
12 p, 669.8 KB |
Women's experiences along the ovarian cancer diagnostic pathway in Catalonia : A qualitative study
/
Vela-Vallespín, Carmen (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Medina-Perucha, Laura (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Jacques-Aviñó, Constanza (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Codern-Bové, Núria (Evaluation and Qualitative Research, ÀreaQ) ;
Harris, Meggan (Independent Researcher) ;
Borras, Josep M (Universitat de Barcelona) ;
Marzo-Castillejo, Mercè (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Early detection of symptoms and prompt diagnosis of ovarian cancer are considered important avenues for improving patient experiences and outcomes. This qualitative study used a phenomenological approach to perform patient interviews, collecting individual accounts of the prediagnostic phase in women diagnosed and treated for ovarian cancer in 2016-2017. [...]
2022 - 10.1111/hex.13681
Health Expectations, Vol. 26 (november 2022) , p. 476-487
|
|
|
8.
|
|
19 p, 3.3 MB |
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
/
Shah, Jennifer B. (University of Pennsylvania) ;
Pueschl, Dana (University of Pennsylvania) ;
Wubbenhorst, Bradley (University of Pennsylvania) ;
Fan, Mengyao (University of Pennsylvania) ;
Pluta, John (University of Pennsylvania) ;
D'Andrea, Kurt (University of Pennsylvania) ;
Hubert, Anna P. (University of Pennsylvania) ;
Shilan, Jake S. (University of Pennsylvania) ;
Zhou, Wenting (University of Pennsylvania) ;
Kraya, Adam A. (University of Pennsylvania) ;
Llop Guevara, Alba (Vall d'Hebron Institut d'Oncologia) ;
Ruan, Catherine (University of Pennsylvania. Perelman School of Medicine) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Feldman, Michael (University of Pennsylvania) ;
Morin, Pat J. (University of Pennsylvania) ;
Nayak, Anupma (University of Pennsylvania) ;
Maxwell, Kara N. (University of Pennsylvania) ;
Domchek, Susan M. (University of Pennsylvania) ;
Nathanson, Katherine L. (University of Pennsylvania) ;
Universitat Autònoma de Barcelona
Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. [...]
2022 - 10.1038/s41467-022-34523-y
Nature communications, Vol. 13 (november 2022)
|
|
|
9.
|
|
16 p, 4.6 MB |
BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling
/
Bradbury, Melissa (Centre de Regulació Genòmica) ;
Castellvi, Josep (Hospital Universitari Vall d'Hebron) ;
Méndez Fernández, Olga (Hospital Universitari Vall d'Hebron) ;
Sanchez Iglesias, Jose Luis (Hospital Universitari Vall d'Hebron) ;
Pérez-Benavente, Assumpció (Hospital Universitari Vall d'Hebron) ;
Gil-Moreno, Antonio 1965- (Centro de Investigación Biomédica en Red de Cáncer) ;
Sabidó, Eduard (Centre de Regulació Genòmica) ;
Santamaría, Anna (Hospital Universitari Vall d'Hebron) ;
Borràs, Eva (Centre de Regulació Genòmica) ;
Vall d'Hebron Institut de Recerca (VHIR)
Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. [...]
2022 - 10.1038/s41598-022-08461-0
Scientific reports, Vol. 12 (march 2022)
|
|
|
10.
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
